Grade migration in prostate cancer: An analysis using the surveillance, epidemiology, and end results registry

Prostate Cancer and Prostatic Diseases

Volumn 10, Issue 4, 2007, Pages 347-351

  Jani, A B ^a   Master, V A ^a   Rossi, P J ^a   Liauw, S L ^b   Johnstone, P A S ^a  

^a EMORY UNIVERSITY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER REGISTRY; CANCER SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; SURVIVAL TIME; TIME SERIES ANALYSIS; TREND STUDY; TUMOR DIFFERENTIATION;

ADULT; AGED; AGED, 80 AND OVER; CELL DIFFERENTIATION; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSTATIC NEOPLASMS; REGISTRIES; SEER PROGRAM; SURVIVAL RATE;

EID: 36949010151     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500977     Document Type: Article

References (30)

1. Jani AB, Hellman S. Early prostate cancer: Clinical decision-making. Lancet 2003; 361: 1045-1053.
2. Frankel S, Smith GD, Donovan J, Neal D. Screening for prostate cancer. Lancet 2003; 361: 1122-1128.
3. Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legler JM, Prorok PC et al. Cancer surveillance series: Interpreting trends in prostate cancer - part 1: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 1999; 91: 1017-1024.
4. Stephenson RA, Smart CR, Mineau GF, James BC, Janerich DT, Dibble RL. The fall in incidence of prostate carcinoma. On the down side of a prostate specific antigen induced peak in incidence - data from the Utah Cancer Registry. Cancer 1996; 77: 1342-1348.
5. Smart CR. The results of prostate carcinoma screening in the U.S. as reflected in the surveillance, epidemiology, and end results program. Cancer 1997; 80: 1835-1844.
6. Stephenson RA, Stanford JL. Population-based prostate cancer trends in the United States: Patterns of change in the era of prostate-specific antigen. World J Urol 1997; 15: 331-335.
7. Schwartz KL, Grignon DJ, Sakr WA, Wood Jr DF. Prostate cancer histologic trends in the metropolitan Detroit area, 1982 to 1996. Urology 1999; 53: 769-774.
8. Farkas A, Schneider D, Perrotti M, Cummings KB, Ward WS. National trends in the epidemiology of prostate cancer, 1973 to 1994: Evidence for the effectiveness of prostate-specific antigen screening. Urology 1998; 52: 444-448.
9. Kondylis FI, Moriarty RP, Bostwick D, Schellhammer PF. Prostate cancer grade assignment: The effect of chronological, interpretive and translation bias. J Urol 2003; 170: 1189-1193.
10. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005; 293: 2095-2101.
11. Jani AB. The effectiveness of combining hormone therapy and radiotherapy in the treatment of prostate cancer. Expert Opin Pharmacother 2004; 5: 2469-2477.
12. Jani AB, Kao J. Postprostatectomy adjuvant versus salvage radiotherapy: a complication-adjusted number-needed-to-treat analysis. Cancer 2005; 103: 1833-1842.
13. Jani AB, Feinstein JM, Pasciak R, Krengel S, Weichselbaum RR. Role of external beam radiotherapy with low-dose-rate brachytherapy in treatment of prostate cancer. Urology 2006; 67: 1007-1011.
14. National Cancer Institute. Surveillance, Epidemiology, and End Results. SEER*Stat 6.2. http://seer.cancer.gov/seerstat/.
15. American joint Committee on Cancer (AJCC). Cancer Staging Manual, 6th edn. Springer-Verlag: New York, 2002.
16. Dawson-Saunders B, Trapp RG. Basic and Clinical Biostatistics. Prentice Hall: East Norwalk, CT, 1990.
17. Smith EB, Frierson Jr HF, Mills SE, Boyd JC, Theodorescu D. Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years: Is there evidence for systematic upgrading? Cancer 2002; 94: 2282-2287.
18. Ghani KR, Grigor K, Tulloch DN, Bollina PR, McNeill SA. Trends in reporting Gleason score 1991 to 2001: Changes in the pathologist's practice. Eur Urol 2005; 47: 196-201.
19. Soh S, Kattan MW, Berkman S, Wheeler TM, Scardino PT. Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy? J Urol 1997; 157: 2212-2218.
20. Jhaveri FM, Klein EA, Kupelian PA, Zippe C, Levin HS. Declining rates of extracapsular extension after radical prostatectomy: Evidence for continued stage migration. J Clin Oncol 1999; 17: 3167-3172.
21. Derweesh IH, Kupelian PA, Zippe C, Levin HS, Brainard J, Magi-Galluzzi C et al. Continuing trends in pathological stage migration in radical prostatectomy specimens. Urol Oncol 2004; 22: 300-306.
22. Master VA, Chi T, Simko JF, Weinberg V, Carroll PR. The independent impact of extended pattern biopsy on prostate cancer stage migration. J Urol 2005; 174: 1789-1793.
23. Johnstone PA, Riffenburgh R, Saunders EL, Willison FW. Grading inaccuracies in diagnostic biopsies revealing prostatic adenocarcinoma: implications for definitive radiation therapy. Int J Radiat Oncol Biol Phys 1995; 32: 479-482.
24. Albertsen PC, Hanley JA, Barrows GH, Penson DF, Kowalczyk PD, Sanders MM et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 2005; 97: 1248-1253.
25. Cooperberg MR, Lubeck DF, Mehta SS, Carroll PR. CaPSURE. Time trends in clinical risk stratification for prostate cancer: Implications for outcomes (data from CaPSURE). J Urol 2003; 170: S21-S27.
26. Epstein JI, Allsbrook Jr WC, Amin MB, Egevad LL. Update on the Gleason grading system for prostate cancer: Results of an international consensus conference of urologic pathologists. Adv Anat Pathol 2006; 13: 57-59.
27. Egevad L, Allsbrook Jr WC, Epstein JI. Current practice of Gleason grading among genitourinary pathologists. Hum Pathol 2005; 36 5-9.
28. Kane CJ, Presti Jr JC, Amling CL, Aronson WJ, Terris MK, Freedland SJ. Changing nature of high risk patients undergoing radical prostatectomy. J Urol 2007; 177: 113-117.
29. Levegrun S, Jackson A, Zelefsky MJ, Venkataraman ES, Skwarchuk MW, Schlegel W et al. Risk group dependence of dose-response for biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer. Radiother Oncol 2002; 63: 11-26.
30. Thompson IM, Canby-Hagino E, Lucia MS. Stage migration and grade inflation in prostate cancer: Will Rogers meets Garrison Keillor. J Natl Cancer Inst 2005; 97: 1236-1237.